Home  »  Finance   »  Adaptimmune Therapeutics plc (ADAP): Are the Stars...

Adaptimmune Therapeutics plc (ADAP): Are the Stars Lining Up for Investors?

For the readers interested in the stock health of Adaptimmune Therapeutics plc (ADAP). It is currently valued at $2.32. When the transactions were called off in the previous session, Stock hit the highs of $2.33, after setting-off with the price of $2.08. Company’s stock value dipped to $1.9688 during the trading on the day. When the trading was stopped its value was $1.94.Recently in News on August 4, 2022, Adaptimmune Reports Second-Quarter Financial Results and Business Update. – Reaffirming financial guidance; Company funded into early 2024 -. You can read further details here

Adaptimmune Therapeutics plc had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $4.1200 on 01/04/22, with the lowest value was $1.2600 for the same time period, recorded on 05/12/22.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Adaptimmune Therapeutics plc (ADAP) full year performance was -32.56%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Adaptimmune Therapeutics plc shares are logging -66.18% during the 52-week period from high price, and 84.13% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.26 and $6.86.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 515742 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Adaptimmune Therapeutics plc (ADAP) recorded performance in the market was -38.13%, having the revenues showcasing 21.47% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 371.83M, as it employees total of 494 workers.

Adaptimmune Therapeutics plc (ADAP) in the eye of market guru’s

During the last month, 0 analysts gave the Adaptimmune Therapeutics plc a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.7900, with a change in the price was noted +0.50. In a similar fashion, Adaptimmune Therapeutics plc posted a movement of +27.47% for the period of last 100 days, recording 532,279 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ADAP is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Adaptimmune Therapeutics plc (ADAP): Stocks Technical analysis and Trends

Raw Stochastic average of Adaptimmune Therapeutics plc in the period of last 50 days is set at 98.92%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 98.55%. In the last 20 days, the company’s Stochastic %K was 71.82% and its Stochastic %D was recorded 58.70%.

If we look into the earlier routines of Adaptimmune Therapeutics plc, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -38.13%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -17.14%, alongside a downfall of -32.56% for the period of the last 12 months. The shares increased approximately by 22.75% in the 7-day charts and went down by 34.10% in the period of the last 30 days. Common stock shares were driven by 21.47% during last recorded quarter.

Leave a Comment

Your email address will not be published.

On Key

Related Posts